J&J’s painkiller is a skin patch that contains fentanyl and is used to control moderate to severe chronic pain. Often, it prescribed for cancer patients.
The French Autorite de la Concurence said J&J deliberately and consistently made an effort to block the approval processes in France for any generic versions of its pain patch. The authority also claims the drugmaker denigrated any generic versions when discussing them with healthcare personnel.
J&J could not immediately be reached for comment, according to CNBC.
More articles on supply chain:
FDA cracks down on homeopathic drugs
Teva Pharmaceuticals to cut more than 25% of workforce, consolidate US sites
Two months after approval, Gilead’s ‘breakthrough’ cancer drug given to just a handful of patients‘
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.